Browse Negotiations Image Banner

Banner Text Velit velaliquam, ultricies eros dolore magna in in doming ullamco sint. Sint doming dignissim in quis pariatur consequat urna eu providerent. Sint dolore ea urna velit doming ea pulvinar.

General Callout

Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.

Accordion

Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.

Heading 1

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Heading 2

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Related content

Dolor commodo suscipit adipiscing suscipit, elit dolore velit. Amet tempuribud velit pariatur ullamco exercitation esse dolore sint velaliquam adipiscing eu pulvinar doming sunt, dignissim velit voluptate ex suscipit sunt ex, duis dignissim nunc tempuribud laboris commodo velit ut. Velit in harmud quis voluptate esse nulla.

Shop Now!

Laboris quis consectetur sed eros velit tempuribud suscipit magna ea consequat laboris. Elit adipiscing quis sunt duis magna nulla velit amet elit ex providerent consectetur tempuribud amet ex commodo urna, magna adipiscing elit sed duis nisi pulvinar, doming pariatur velaliquam quis providerent fugiat ea aliquip sit ut nisi sunt pulvinar eu velit.

grey rec centre

Call to action

Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate

Primary Button Secondary Button

Search by drug, manufacturer, or indication

Displaying 951 - 960 of 1165

Avastin (bevacizumab)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Metastatic Colorectal Cancer

Last updated August 21, 2017

Ninlaro (ixazomib)

Status:

Negotiations were not pursued

Manufacturer:

Takeda Canada Inc.

Indication:

Multiple Myeloma

Last updated August 18, 2017

Butrans (buprenorphine)

Status:

Concluded without agreement

Manufacturer:

Purdue Pharma

Indication:

Pain, persistent (moderate intensity)

Last updated August 18, 2017

Caprelsa (vandetanib)

Status:

Concluded without agreement

Manufacturer:

Sanofi Genzyme Canada

Indication:

Medullary Thyroid Cancer

Last updated August 16, 2017

Jakavi (ruxolintib)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Polycythemia vera

Last updated August 8, 2017

Alecensaro (alectinib)

Status:

Negotiations were not pursued

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Non-Small Cell Lung Cancer (with CNS metastases)

Last updated July 31, 2017

Basaglar (Insulin Glargine)

Status:

Concluded with an LOI

Manufacturer:

Eli Lilly Canada Inc.

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated July 7, 2017

Mifegymiso (mifepristone and misoprostol)

Status:

Concluded with an LOI

Manufacturer:

Celopharma

Indication:

Medical termination of pregnancy

Last updated July 5, 2017

Votrient (pazopanib hydrochloride)

Status:

Concluded with an LOI

Manufacturer:

GlaxoSmithKline Inc.

Indication:

Metastatic Renal Cell Carcinoma

Last updated July 3, 2017

Imbruvica (ibrutinib)

Status:

Concluded with an LOI

Manufacturer:

Janssen Inc.

Indication:

Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

Last updated June 27, 2017